ArticleNature2017
Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination.
Open access · bronzeAbstract read
In one paragraph
Article in Nature, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 530 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
530citing papers in PubMed, 1 pooled it
88.5field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
530 citing papers in PubMed, 1 synthesis or guideline pooled it, 875 citations in OpenAlex.
- A systematic and thematic analysis of the top 100 cited articles on mRNA vaccine indexed in Scopus database.Human vaccines & immunotherapeutics · 2022Pooled it
- Enhanced immunogenicity and dose-sparing efficacy of self-amplifying RNA vaccines against seasonal influenza across subtypes.Emerging microbes & infections · 2026Article
- Restoration of p53 function via hybrid strontium sulfite nanoparticles modified LNP improves the antitumor efficacy in breast cancers.Cancer gene therapy · 2026Article
- PEG-associated efficacy loss in lipid nanoparticles persists across formulation modifications for mRNA delivery.Drug delivery and translational research · 2026Article
- How lipid nanoparticles evolved from models of biological membranes to systems that enable RNA therapeutics.Nature nanotechnology · 2026Article
- mRNA lipid nanoparticle vaccines: current status, challenges and future prospects.Molecular biomedicine · 2026Review
- Beyond the genetic code: orchestrating epigenetic and immune landscapes with multivalent mRNA-exosome vaccines.Precision clinical medicine · 2026Review
- A ubiquitinated E2-based mRNA vaccine confers complete protection against lethal challenge with classical swine fever virus.Journal of virology · 2026Article
- Thio-modification effects on mRNA translation using a PureCap-based capping method.RSC chemical biology · 2026Article
- Enhancing mRNA stability and translational potential through tailored modifications at the 3' end.RSC chemical biology · 2026Article
- PEG-associated efficacy loss in lipid nanoparticles persists across formulation modifications for mRNA delivery.Research square · 2026Article
- Ten Years of Congenital Zika Syndrome: From Outbreak to a Decade of Clinical, Therapeutic, and Preventive Advances in a Tropical Disease Context.Tropical medicine and infectious disease · 2026Review
- mRNA vaccines for viral diseases: mechanism, advances, and future perspective.Molecular biology reports · 2026Review
- Uridine analogs prevent stress granule formation, not by blocking PKR recognition, but by inhibiting the synthesis of T7 RNA polymerase byproducts.RNA (New York, N.Y.) · 2026Article
- An mRNA vaccine confers enhanced protection against herpes simplex virus through an IFN-I-dependent pathway.NPJ vaccines · 2026Article
- Beyond the Sequence: Chemical and Topological Design and Innovations in mRNA Therapeutics.Chemical reviews · 2026Review
- Comparison of Vaccine Platforms for Machupo Virus.Vaccines · 2026Article
- RNA Therapeutics in Viral Infections and Cancer: Mechanisms, Challenges, and Prospects: A Review.Pharmaceutics · 2026Review
- N1MΨU-modified mRNA vaccines break the mold in fish by enhancing innate immune activation.Molecular therapy. Nucleic acids · 2026Article
- Tumor Vaccines in Hepatocellular Carcinoma: Advances, Challenges, and the Path Toward Precision Immunotherapy.Journal of clinical and translational hepatology · 2026Review
470 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
37 authors at 9 institutions in 3 countries.
Norbert PardiDepartment of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA.
Michael J HoganDepartment of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA.
Rebecca S PelcViral Pathogenesis Section, National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, Maryland 20892, USA.
Hiromi MuramatsuDepartment of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA.
Hanne AndersenBioqual Inc., Rockville, Maryland 20850-3220, USA.
Christina R DeMasoViral Pathogenesis Section, National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, Maryland 20892, USA.
Kimberly A DowdViral Pathogenesis Section, National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, Maryland 20892, USA.
Laura L SutherlandDuke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina 27710, USA.
Richard M ScearceDuke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina 27710, USA.
Robert ParksDuke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina 27710, USA.
Wendeline WagnerBioqual Inc., Rockville, Maryland 20850-3220, USA.
Alex GranadosBioqual Inc., Rockville, Maryland 20850-3220, USA.
Jack GreenhouseBioqual Inc., Rockville, Maryland 20850-3220, USA.
Michelle WalkerBioqual Inc., Rockville, Maryland 20850-3220, USA.
Elinor WillisDepartment of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA.
Jae-Sung YuDuke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina 27710, USA.
Charles E McGeeDuke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina 27710, USA.
Gregory D SempowskiDuke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina 27710, USA.
Barbara L MuiAcuitas Therapeutics, Vancouver, British Columbia V6T 1Z3, Canada.
Ying K TamAcuitas Therapeutics, Vancouver, British Columbia V6T 1Z3, Canada.
Yan-Jang HuangDiagnostic Medicine and Pathobiology, College of Veterinary Medicine and the Biosecurity Research Institute, Kansas State University, Manhattan, Kansas 66506, USA.
Dana VanlandinghamDiagnostic Medicine and Pathobiology, College of Veterinary Medicine and the Biosecurity Research Institute, Kansas State University, Manhattan, Kansas 66506, USA.
Veronica M HolmesDepartment of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA.
Harikrishnan BalachandranCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215 USA.
Sujata SahuCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215 USA.
Michelle LiftonCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215 USA.
Stephen HiggsDiagnostic Medicine and Pathobiology, College of Veterinary Medicine and the Biosecurity Research Institute, Kansas State University, Manhattan, Kansas 66506, USA.
Scott E HensleyDepartment of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA.
Thomas D MaddenAcuitas Therapeutics, Vancouver, British Columbia V6T 1Z3, Canada.
Michael J HopeAcuitas Therapeutics, Vancouver, British Columbia V6T 1Z3, Canada.
Katalin KarikóBioNTech RNA Pharmaceuticals, An der Goldgrube 12, 55131 Mainz, Germany.
Sampa SantraCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215 USA.
Barney S GrahamVaccine Research Center, National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, Maryland 20892, USA.
Mark G LewisBioqual Inc., Rockville, Maryland 20850-3220, USA.
Theodore C PiersonViral Pathogenesis Section, National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, Maryland 20892, USA.
Barton F HaynesDuke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina 27710, USA.
Drew WeissmanDepartment of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA.
Duke University · USUniversity of Pennsylvania · USBioqual · USAcuitas Therapeutics (Canada) · CABeth Israel Deaconess Medical Center · USNational Institutes of Health · USKansas State University · USBioNTech (Germany) · DENational Institute of Allergy and Infectious Diseases · US
Funding
Virus biology scientific research support componentUM1AI100645 · NIAID · DUKE UNIVERSITY · PI HARRISON, STEPHEN COPLAN · 2012 to 2018
$204.7MUsing a tonsil organoid system to probe conditions for the induction of protective antibody and T cell responses to influenza.U19AI057229 · NIAID · STANFORD UNIVERSITY · PI Mark Morris Davis · 2003 to 2026
$88.5MThe humoral response to Zika virus infection and vaccinationZIAAI001209 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI PIERSON, THEODORE · 2016 to 2025
$22.0MRegional Biocontainment Laboratory (RBL)UC6AI058607 · NIAID · DUKE UNIVERSITY · PI WILLIAMS, R SANDERS · 2003 to 2005
$16.3MTRAINING IN HIV PATHOGENESIST32AI007632 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI Frederic D Bushman, James L. Riley · 2000 to 2026
$10.6MImmune System Development and RegulationT32AI055428 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI ALLMAN, DAVID M, OLIVER, PAULA MARIA · 2003 to 2025
$4.2MRNA DELIVERY FOR DENDRITIC CELL HIV ANTIGEN PREVENTIONR01AI050484 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI WEISSMAN, DREW · 2002 to 2011
$3.6MVMD-PhD Training in Infectious Disease-Related ResearchT32AI070077 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI Michael Lee Atchison · 2008 to 2026
$3.5MNucleoside modified mRNA based HIV vaccineR01AI124429 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI WEISSMAN, DREW · 2016 to 2019
$3.4MOptimizing HIV Env immuogens for T and B cell vaccine responsesR01AI090788 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI HOXIE, JAMES A, WEISSMAN, DREW · 2010 to 2013
$2.3MTAT ASSOCIATED KINASE REGULATION OF HIV GENE EXPRESSIONR01AI041860 · NIAID · UNIVERSITY OF TEXAS SW MED CTR/DALLAS · PI VERMA, UDIT N · 1997 to 2005
$1.7MNIAID NIH HHS R01 AI041860NIAID NIH HHS R01 AI050484NIAID NIH HHS R01 AI090788NIAID NIH HHS R01 AI124429NIAID NIH HHS T32 AI007632NIAID NIH HHS T32 AI055428NIAID NIH HHS T32 AI070077NIAID NIH HHS U19 AI057229NIAID NIH HHS UC6 AI058607NIAID NIH HHS UM1 AI100645
Abstract
Zika virus (ZIKV) has recently emerged as a pandemic associated with severe neuropathology in newborns and adults. There are no ZIKV-specific treatments or preventatives. Therefore, the development of a safe and effective vaccine is a high priority. Messenger RNA (mRNA) has emerged as a versatile and highly effective platform to deliver vaccine antigens and therapeutic proteins. Here we demonstrate that a single low-dose intradermal immunization with lipid-nanoparticle-encapsulated nucleoside-modified mRNA (mRNA-LNP) encoding the pre-membrane and envelope glycoproteins of a strain from the ZIKV outbreak in 2013 elicited potent and durable neutralizing antibody responses in mice and non-human primates. Immunization with 30 μg of nucleoside-modified ZIKV mRNA-LNP protected mice against ZIKV challenges at 2 weeks or 5 months after vaccination, and a single dose of 50 μg was sufficient to protect non-human primates against a challenge at 5 weeks after vaccination. These data demonstrate that nucleoside-modified mRNA-LNP elicits rapid and durable protective immunity and therefore represents a new and promising vaccine candidate for the global fight against ZIKV.
Indexed as
AnimalsAntibodies, NeutralizingAntibodies, ViralAntigens, ViralFemaleGlycoproteinsInjections, IntradermalMacaca mulattaMiceMice, Inbred BALB CMice, Inbred C57BLNanoparticlesRNA, MessengerRNA StabilityRNA, ViralTime FactorsAntibodies, NeutralizingAntibodies, ViralAntigens, ViralGlycoproteinsRNA, MessengerRNA, ViralViral Envelope ProteinsViral Vaccines
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.